https://www.mdanderson.org/newsroom/poziotinib-is-active-in-egfr-exon-20-mutant-non-small-cell-lung-cancer.h00-159541323.html
Jul 11, 2022 - A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by...
poziotinibactiveegfrexonmutant
https://www.biospace.com/spectrum-provides-poziotinib-update-after-successful-pre-nda-meeting-with-the-fda
FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion...
meeting withspectrumprovidespoziotinibupdate